Short Interest in Stereotaxis Inc. (NYSEAMERICAN:STXS) Expands By 21.2%

Stereotaxis Inc. (NYSEAMERICAN:STXS) saw a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling 3,271,536 shares, a growth of 21.2% from the January 29th total of 2,699,750 shares. Approximately 4.3% of the shares of the stock are sold short. Based on an average daily volume of 542,840 shares, the short-interest ratio is presently 6.0 days. Based on an average daily volume of 542,840 shares, the short-interest ratio is presently 6.0 days. Approximately 4.3% of the shares of the stock are sold short.

Stereotaxis Trading Up 0.5%

Shares of STXS traded up $0.01 during midday trading on Thursday, reaching $2.21. 715,911 shares of the company were exchanged, compared to its average volume of 537,432. Stereotaxis has a 1-year low of $1.54 and a 1-year high of $3.59. The stock has a 50-day moving average price of $2.33 and a 200-day moving average price of $2.60. The company has a market cap of $206.24 million, a price-to-earnings ratio of -7.89 and a beta of 1.38.

Analysts Set New Price Targets

Several research analysts have recently issued reports on STXS shares. Roth Mkm reaffirmed a “buy” rating and set a $4.00 price target on shares of Stereotaxis in a research note on Wednesday, November 12th. Citigroup initiated coverage on shares of Stereotaxis in a research report on Tuesday, December 16th. They set an “outperform” rating for the company. Citizens Jmp initiated coverage on Stereotaxis in a research note on Tuesday, December 16th. They issued a “market outperform” rating and a $4.00 target price on the stock. Finally, UBS Group set a $4.00 target price on shares of Stereotaxis in a research note on Wednesday, November 5th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, Stereotaxis currently has an average rating of “Buy” and a consensus price target of $4.00.

Institutional Investors Weigh In On Stereotaxis

A number of hedge funds have recently bought and sold shares of STXS. Prescott Group Capital Management L.L.C. boosted its stake in shares of Stereotaxis by 44.5% during the 2nd quarter. Prescott Group Capital Management L.L.C. now owns 1,139,252 shares of the company’s stock valued at $2,415,000 after buying an additional 350,600 shares during the last quarter. Geode Capital Management LLC boosted its stake in Stereotaxis by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,478,201 shares of the company’s stock valued at $3,135,000 after acquiring an additional 13,891 shares during the last quarter. Warberg Asset Management LLC grew its holdings in Stereotaxis by 260.1% during the 2nd quarter. Warberg Asset Management LLC now owns 1,201,500 shares of the company’s stock worth $2,547,000 after acquiring an additional 867,878 shares in the last quarter. Rhumbline Advisers raised its position in shares of Stereotaxis by 223.7% during the 2nd quarter. Rhumbline Advisers now owns 148,913 shares of the company’s stock valued at $316,000 after acquiring an additional 102,916 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in Stereotaxis in the second quarter worth about $78,000. Institutional investors and hedge funds own 45.35% of the company’s stock.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.